Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Howard I. Scher(Kantonsspital Baselland Standort Bruderholz), Martin Fleisher(Memorial Sloan Kettering Cancer Center), Steven M. Larson(Memorial Sloan Kettering Cancer Center), Michael J. Morris(The University of Texas Southwestern Medical Center), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center), Daniel C. Danila, Susan F. Slovin(Cornell University), Mithat Gönen(Memorial Sloan Kettering Cancer Center), Isan Chen(Dana (United States)), Peter J. Rix(Dana (United States)), Jeffrey H. Hager(Dana (United States)), Josef J. Fox(Dana (United States)), Edna Chow Maneval(Dana (United States))
Cited by 264
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k